#None #Amsterdam #iOnctura #Neil Gallagher #Anthony Mancini

iOnctura Strengthens Leadership with Two New Board Members

In a significant move aimed at propelling its growth and expanding its expertise in the field of oncology, iOnctura, a clinical-stage precision oncology company, has welcomed two distinguished professionals to its Board of Directors. On July 24, 2025, the company announced that Dr. Neil Gallagher and Anthony Mancini have joined as Non-Executive Directors, augmenting its strategic capabilities in both medical and commercial realms.

Who Are the New Board Members?

Dr. Neil Gallagher

Dr. Neil Gallagher, who previously held the esteemed position of Chief Medical Officer at AbbVie and most recently served as President of Research and Development at Syndax Pharmaceuticals, brings a wealth of experience in oncology drug development. With a background that includes key positions at renowned firms like Amgen and Novartis, Dr. Gallagher's expertise is expected to be instrumental as iOnctura navigates the complexities of oncology innovations. His prior involvement in FDA-approved development programs underscores his capability in guiding clinical advancements, particularly for patients faced with hard-to-treat cancers.

When discussing his new role, Dr. Gallagher expressed immense enthusiasm about joining iOnctura, stating, "The company’s dedication to addressing the needs of patients battling overlooked cancers resonates deeply with me. I am eager to contribute to the next phase of clinical and corporate growth for iOnctura." This sentiment reflects a shared vision of success that aligns with iOnctura’s mission to innovate within precision oncology.

Anthony Mancini

Joining Dr. Gallagher is Anthony Mancini, currently the Global Chief Commercial Officer at Revolution Medicines. With over 30 years of experience in biopharma, he boasts a track record of launching successful products in the oncology space, having previously been Chief Operating Officer at Genmab and holding pivotal roles at Bristol Myers Squibb. Mancini's extensive background in commercialization and operations will provide iOnctura with insights and strategies to enhance its market footprint.

Mancini noted, "iOnctura’s innovative pipeline represents a unique opportunity to meet urgent medical needs. I am honored to be part of the board at such a crucial time and look forward to helping translate promising science into significant clinical outcomes for patients globally." His perspective on drug commercialization will likely accelerate the company’s ability to bring transformative therapies to market.

Implications for iOnctura

The appointment of these two seasoned professionals comes at a critical time for iOnctura. The company is advancing its robust oncology pipeline, which is focused on developing first-in-class therapies for cancers that are often neglected. By leveraging Dr. Gallagher’s and Mancini’s invaluable insights, iOnctura aims to enhance its strategic direction and operational effectiveness, ultimately leading to better health outcomes for patients.

Catherine Pickering, CEO and co-founder of iOnctura, emphasized the importance of these appointments: "We are thrilled to welcome Neil and Anthony to our Board at this pivotal time in iOnctura's growth. Their expertise will be instrumental as we advance our innovative pipeline toward the market." This belief in the synergy between the new board members and iOnctura's vision highlights the strategic planning that underpins these appointments.

Conclusion

As iOnctura embarks on this next chapter of its journey, it does so with the guided expertise of leaders who possess a deep understanding of both medical and commercial landscapes in the oncology domain. The hope is that with their leadership, the company will be better positioned to deliver groundbreaking treatments that will truly make a difference in the lives of cancer patients worldwide. The decision to enhance the Board's capabilities indicates not only ambition but also a commitment to realizing impactful advancements in oncology.

For more insightful news and updates on iOnctura and its innovative endeavors in the precision oncology landscape, stay tuned to industry reports and press releases.